Ousted CEO Pourhassan sues CytoDyn to cover his attorney’s fees

Pourhassan is facing securities fraud charges in Maryland in connection with statements about CytoDyn's drug candidate and stock sales.

Previous Local company launches fintech to help its customers buy manufactured homes
Next $2B Dallas tech firm ShiftKey expands team, hires four executives